revenue

Vertex Pharmaceuticals Review: control of cystic fibrosis

Vertex PharmaceuticalsVRTX287,00 $ Vertex Pharmaceuticals (NASDAQ: VRTX) - American manufacturer of drugs for the treatment of cystic fibrosis. The company is not so expensive and even very profitable. But there are some worrying things.

Corteva review – you always want to eat

Corteva IncCTVA53,90 $ The crisis of 2020 and geopolitical unrest in 2022 once again reminded investors, what are the sectors of the economy, who lend themselves differently to pressure in times of uncertainty.

Scroll to Top